IDEAYA Biosciences, Inc. IDYA
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -24.30%
- 1 year
- -21.01%
5D -3.95 (-12.60%)
- Market cap
- 2.53B
- Revenue (ttm)
- 36.54M
- EPS (ttm)
- -4.50
- Shares out
- 96.69M
- Forward P/E
- -6.24
- YTD return
- -24.30%
- 1-year return
- -21.01%
- 50-day average
- 34.81
- 200-day average
- 33.77
- Enterprise value
- 1.75B
- Volume
- 1.42M
- Avg volume
- 932.95K
- Open
- 26.57
- Previous close
- 26.49
- Day's range
- 25.75 – 27.44
- 52-week range
- 25.75 – 42.68
- Beta
- 0.08
- Analysts
- Strong Buy
- Price target
- 50.69 (+93.7%)
- Earnings date
- Feb 16, 2027
Key statistics
- Price / sales
- 69.26
- Price / book
- 2.32
- Revenue growth
- -95.10%
- Free cash flow
- -214.22M
- Total cash
- 838.54M
- Total debt
- 29.70M
- Return on equity
- -38.46%
- Short % of float
- 9.89%
Fundamental scorecard
5 of 25 checks passed on IDYA’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 30.00
- Target (mean)
- 50.69
- Target (high)
- 66.00
- Strong buy2
- Buy12
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate -1.18.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | -1.18 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -1.18 | -1.22 | -0.04 | -3.39% |
| Aug 4, 2026 | Jun 30, 2026 | -1.06 | -1.22 | -0.16 | -15.09% |
| May 5, 2026 | Mar 31, 2026 | -1.07 | -1.11 | -0.04 | -3.74% |
| Feb 17, 2026 | Dec 31, 2025 | -0.95172 | -0.94 | +0.01 | +1.23% |
| Nov 4, 2025 | Sep 30, 2025 | -0.94597 | 1.33 | +2.28 | +240.60% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Mizuho | main | Outperform | Outperform |
| Nov 5, 2026 | Citigroup | main | Buy | Buy |
| Nov 4, 2026 | RBC Capital | main | Outperform | Outperform |
| Nov 4, 2026 | Truist Securities | reit | Buy | Buy |
| Nov 4, 2026 | Guggenheim | main | Buy | Buy |
| Nov 4, 2026 | Wedbush | main | Outperform | Outperform |
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ideayabio.com
News
IDEAYA Biosciences, Inc. $IDYA Shares Bought by Aberdeen Group plc
Ideaya Biosciences: Staying Bullish On Darovasertib NDA Submission And More RBC Capital Reiterates Outperform on IDEAYA Biosciences, Maintains $45 Price Target
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcript Reported Sunday, IDEAYA Nominates IDE101, Potential First-In-Class Dual CDK Inhibitor Targeting CDKN2A-Deficiency In Solid Tumors, With IND Filing Planned For H1 2027
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors Mizuho Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $39
Citigroup Maintains Buy on IDEAYA Biosciences, Raises Price Target to $66
Your note
Sign in to keep a note on IDYA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HATA YUJIRO S. | Chief Executive Officer | Sale | Oct 5, 2026 | 690,695 |
| RUIZ BRISENO ANDRES | Officer | Sale | Jul 6, 2026 | 26,466 |
| SNYDER DOUGLAS B | General Counsel | Stock Award(Grant) | Nov 27, 2025 | 2,080 |
| STEIN JEFFREY | Director | Purchase | Mar 1, 2026 | 61,007 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.97% | 14,472,529 | 378.75M | Sep 29, 2026 |
| Blackrock Inc. | 9.87% | 9,548,534 | 249.89M | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 8.92% | 8,622,814 | 225.66M | Sep 29, 2026 |
| Capital Research Global Investors | 5.52% | 5,340,938 | 139.77M | Sep 29, 2026 |
| Baker Bros. Advisors, LP | 5.18% | 5,010,030 | 131.11M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.46% | 4,311,706 | 112.84M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 5.38% | 5,202,950 | 136.16M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.95% | 4,790,196 | 125.36M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.07% | 2,964,950 | 77.59M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.42% | 2,337,660 | 61.18M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.64% | 1,586,602 | 41.52M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.42% | 1,369,224 | 35.83M | Sep 29, 2026 |
